Cargando…

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

PURPOSE: NLG207 (formerly CRLX101) is a nanoparticle–drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT). The present study sought to characterize the complex pharmacokinetics (PK) of NLG207 and better describe CPT release from nanoparticles using a population PK (popPK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Keith T., Huitema, Alwin D. R., Dorlo, Thomas P. C., Peer, Cody J., Cordes, Lisa M., Sciuto, Linda, Wroblewski, Susan, Pommier, Yves, Madan, Ravi A., Thomas, Anish, Figg, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515962/
https://www.ncbi.nlm.nih.gov/pubmed/32897402
http://dx.doi.org/10.1007/s00280-020-04134-9
_version_ 1783586912219430912
author Schmidt, Keith T.
Huitema, Alwin D. R.
Dorlo, Thomas P. C.
Peer, Cody J.
Cordes, Lisa M.
Sciuto, Linda
Wroblewski, Susan
Pommier, Yves
Madan, Ravi A.
Thomas, Anish
Figg, William D.
author_facet Schmidt, Keith T.
Huitema, Alwin D. R.
Dorlo, Thomas P. C.
Peer, Cody J.
Cordes, Lisa M.
Sciuto, Linda
Wroblewski, Susan
Pommier, Yves
Madan, Ravi A.
Thomas, Anish
Figg, William D.
author_sort Schmidt, Keith T.
collection PubMed
description PURPOSE: NLG207 (formerly CRLX101) is a nanoparticle–drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT). The present study sought to characterize the complex pharmacokinetics (PK) of NLG207 and better describe CPT release from nanoparticles using a population PK (popPK) model. METHODS: From 27 patients enrolled on two phase II clinical trials (NCT02769962 and NCT03531827), dense sampling was performed up to 48 h post-administration of NLG207 during cycle one and six of treatment; samples were also collected at ~ 360 h post-dose. Conjugated and free CPT concentrations were quantified from each sample, resulting in 477 observations to build a popPK model using non-linear mixed-effects modeling. RESULTS: The PK of NLG207 was characterized by combining two linear two-compartment models with first-order kinetics each to describe nanoparticle-bound (conjugated) and free CPT. Allometric scaling based on body weight provided the best body-size descriptor for all PK parameters. The typical volumes of distribution of the conjugated CPT central and free CPT central compartments were 3.16 L (BSV CV%; 18.1%) and 21.1 L (CV%; 79.8%), respectively. CPT release from the nanoparticle formulation was characterized via an initial rapid clearance of 5.71 L/h (CV%; 62.6%), which decreased via first-order decay (estimated half-life of 0.307 h) to the steady-state value of 0.0988 L/h (CV%; 33.5%) by ~ 4 h after end of infusion. Renal clearance of free CPT was 0.874 L/h (CV%; 42.2%). CONCLUSION: The popPK model confirmed nanoparticle behavior of conjugated CPT and mechanistically characterized CPT release from NLG207. The current analysis provides a strong foundation for future study as a potential predictive tool in ongoing NLG207 clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00280-020-04134-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7515962
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-75159622020-10-07 Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors Schmidt, Keith T. Huitema, Alwin D. R. Dorlo, Thomas P. C. Peer, Cody J. Cordes, Lisa M. Sciuto, Linda Wroblewski, Susan Pommier, Yves Madan, Ravi A. Thomas, Anish Figg, William D. Cancer Chemother Pharmacol Original Article PURPOSE: NLG207 (formerly CRLX101) is a nanoparticle–drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT). The present study sought to characterize the complex pharmacokinetics (PK) of NLG207 and better describe CPT release from nanoparticles using a population PK (popPK) model. METHODS: From 27 patients enrolled on two phase II clinical trials (NCT02769962 and NCT03531827), dense sampling was performed up to 48 h post-administration of NLG207 during cycle one and six of treatment; samples were also collected at ~ 360 h post-dose. Conjugated and free CPT concentrations were quantified from each sample, resulting in 477 observations to build a popPK model using non-linear mixed-effects modeling. RESULTS: The PK of NLG207 was characterized by combining two linear two-compartment models with first-order kinetics each to describe nanoparticle-bound (conjugated) and free CPT. Allometric scaling based on body weight provided the best body-size descriptor for all PK parameters. The typical volumes of distribution of the conjugated CPT central and free CPT central compartments were 3.16 L (BSV CV%; 18.1%) and 21.1 L (CV%; 79.8%), respectively. CPT release from the nanoparticle formulation was characterized via an initial rapid clearance of 5.71 L/h (CV%; 62.6%), which decreased via first-order decay (estimated half-life of 0.307 h) to the steady-state value of 0.0988 L/h (CV%; 33.5%) by ~ 4 h after end of infusion. Renal clearance of free CPT was 0.874 L/h (CV%; 42.2%). CONCLUSION: The popPK model confirmed nanoparticle behavior of conjugated CPT and mechanistically characterized CPT release from NLG207. The current analysis provides a strong foundation for future study as a potential predictive tool in ongoing NLG207 clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00280-020-04134-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-09-08 2020 /pmc/articles/PMC7515962/ /pubmed/32897402 http://dx.doi.org/10.1007/s00280-020-04134-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Schmidt, Keith T.
Huitema, Alwin D. R.
Dorlo, Thomas P. C.
Peer, Cody J.
Cordes, Lisa M.
Sciuto, Linda
Wroblewski, Susan
Pommier, Yves
Madan, Ravi A.
Thomas, Anish
Figg, William D.
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
title Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
title_full Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
title_fullStr Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
title_full_unstemmed Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
title_short Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
title_sort population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of nlg207 in adults with advanced solid tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515962/
https://www.ncbi.nlm.nih.gov/pubmed/32897402
http://dx.doi.org/10.1007/s00280-020-04134-9
work_keys_str_mv AT schmidtkeitht populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT huitemaalwindr populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT dorlothomaspc populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT peercodyj populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT cordeslisam populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT sciutolinda populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT wroblewskisusan populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT pommieryves populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT madanravia populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT thomasanish populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors
AT figgwilliamd populationpharmacokineticanalysisofnanoparticleboundandfreecamptothecinafteradministrationofnlg207inadultswithadvancedsolidtumors